Walter & Keenan Wealth Management’s Quest Diagnostics DGX Stock Holding History

Walter & Keenan Wealth Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,407	Closed	-$220K	–	144
2022 Q4	$220K	Buy	+1,407	New	+$202K	0.09%	133
2022 Q1	–	Sell	-1,400	Closed	-$242K	–	148
2021 Q4	$242K	Hold	1,400	–	–	0.08%	138
2021 Q3	$203K	Buy	+1,400	New	+$205K	0.07%	150
2021 Q1	–	Sell	-1,745	Closed	-$208K	–	147
2020 Q4	$208K	Buy	+1,745	New	+$213K	0.08%	139

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Walter & Keenan Wealth Management's DGX Position: Q1 2023 in Review

Walter & Keenan Wealth Management sold out of Quest Diagnostics (DGX) in Q1 2023, closing a stake of 1,407 shares — an estimated $220K sold.

Walter & Keenan Wealth Management first reported a position in DGX in Q4 2020 and held it in 4 quarters. The position peaked at $242K in Q4 2021. 834 funds tracked by Wall St. Rank hold DGX as of Q1 2023.

Walter & Keenan Wealth Management reported no remaining Quest Diagnostics position as of Q1 2023 after selling out during the quarter.
Walter & Keenan Wealth Management sold 1,407 Quest Diagnostics shares in Q1 2023, an estimated $220K.
Walter & Keenan Wealth Management first reported a position in Quest Diagnostics in Q4 2020 and held it in 4 quarters.
Walter & Keenan Wealth Management's Quest Diagnostics position peaked at $242K in Q4 2021.
834 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2023.

Based on Walter & Keenan Wealth Management's 13F filing for Q1 2023, filed 26 Apr 2023.